Nedocromil sodium prevents the release of 15-hydroxyeicosatetraenoic acid from human bronchial epithelial cells exposed to toluene diisocyanate in vitro.
Int Arch Allergy Appl Immunol
; 92(1): 16-22, 1990.
Article
em En
| MEDLINE
| ID: mdl-2174022
ABSTRACT
The in vivo exposure to an asthmogenic stimulus, toluene diisocyanate (TDI), causes airway epithelial damage associated with inflammation and increased bronchial hyperresponsiveness. The latter mechanisms might partly be mediated by the release of eicosanoids from bronchial epithelial cells. We have previously demonstrated that the in vitro exposure of bronchial epithelial cells to TDI results in the release of immunoreactive 15-hydroxyeicosatetraenoic acid (15-HETE), a product of activation of the 15-lipoxygenase pathway with inflammatory properties. In the present study we show that TDI-induced release of 15-HETE from epithelial cells can be prevented by nedocromil sodium, an anti-asthmatic drug with anti-inflammatory properties. This mode of action of the compound may explain its clinical effectiveness in asthma.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Brônquios
/
Anti-Inflamatórios não Esteroides
/
Ácidos Hidroxieicosatetraenoicos
/
Tolueno 2,4-Di-Isocianato
/
Quinolonas
Tipo de estudo:
Incidence_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Int Arch Allergy Appl Immunol
Ano de publicação:
1990
Tipo de documento:
Article
País de afiliação:
Itália